101. Regulatory T-cells in type 1 diabetes
- Author
-
Amy E. Juedes and Matthias von Herrath
- Subjects
Autoimmune disease ,Type 1 diabetes ,business.industry ,T-Lymphocytes ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Disease progression ,Autoimmunity ,Immunosuppression ,medicine.disease ,medicine.disease_cause ,Diabetes Mellitus, Type 1 ,Endocrinology ,Cytokine ,Diabetes mellitus ,Immunology ,Internal Medicine ,medicine ,Animals ,Humans ,IL-2 receptor ,business - Abstract
Type 1 diabetes is a T-cell-mediated autoimmune disease, resulting in destruction of the insulin-producing beta cells in the pancreas. Disease progression is thought to involve the action of T-cells, particularly those producing Th1-type cytokines. Given the complexity in understanding the precise etiology of autoimmune diseases, the diversity of autoantigens, and the variability that exists between individual patients, it might be very difficult to eliminate autoaggressive T-cell responses without resorting to generalized means of immunosuppression. However, recent evidence shows that autoimmune processes are composed not only of autoaggressive T-cell responses but also of autoreactive regulatory components. Enhancing regulatory T-cell responses, therefore, has become an area of intense focus as a means of treating autoimmune diseases like type 1 diabetes. This review will concentrate on two different types of regulatory T-cells, the naturally occurring (‘professional’) CD4+CD25+ T-cells and antigen-induced (‘adaptive’) CD4+ Th2-like regulatory T-cells. Copyright © 2004 John Wiley & Sons, Ltd.
- Published
- 2004